Sun Pharma inks licensing pact with AstraZeneca to introduce products in China

By: |
New Delhi | Published: November 6, 2019 10:47:50 AM

The agreement will help to bring cost-effective and quality drugs to patients in China, the Mumbai-based company said in a statement.

sun pharma, sun pharma share, sun pharma news, sun pharma price, sun pharma stockShares of the company were trading at Rs 446 apiece, up 3.75 per cent from their previous close on the BSE. (Reuters)

Drug major Sun Pharma on Wednesday said it has entered a licensing agreement with AstraZeneca UK to introduce certain novel ready-to-use infusion oncology products in China. The agreement will help to bring cost-effective and quality drugs to patients in China, the Mumbai-based company said in a statement. As per the terms of the agreement, Sun Pharma will be responsible for development, regulatory filings and manufacturing the products covered in the agreement, while AstraZeneca will exclusively promote and distribute these products in China, it added.

The initial tenure of the agreement is 10 years from the first commercial sale of the said products in China, Sun Pharmaceutical Industries said. The company, however, did not share financial terms of the agreement. “AstraZeneca’s leadership position will help us to make our products available to patients and doctors in China,” Sun Pharma Director of Corporate Development Kal Sundaram said.

ALSO READ | Troubles continue for Indian pharma as three major drugmakers get new warning letter from FDA

The company sees a great potential to introduce its speciality and generic products in the growing China market and this licensing agreement is another positive step in that direction, he added. Shares of the company were trading at Rs 446 apiece, up 3.75 per cent from their previous close on the BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Indigo likely to announce pact with Qatar Airways
2Adani Group moves Bombay HC seeking to stop investment into GVK Airport Holdings
3M&A deals to hit $52.10 billion in 2019: Report